Member Area

FarmavitaR+ : Regulatory Affairs Network

Tuesday
Feb 09th
Home
Regulatory Affairs News
Difficulty in readability testing

 

The Difficulty in Readability Testing

 

Since readability testing became a necessity for better patient understanding of leaflets, there has been a plethora of ways to test a leaflet.   To the outsider, presenting a leaflet to a participant, asking a set of preset questions and recording the responses could appear to be enough to gauge the user friendliness of a Package Leaflet (PL).  However, a simple yes/no dichotomic approach quickly yields an unforeseen variable which can aptly be demonstrated in the following hypothetical situation. 

Intellectual Propriatery News
FDA Improves Generic Drug Access

FDA Announces Measures to Improve Generic Drug Access

The Food and Drug Administration (FDA) im March 2004 announced that it will provide more information to the public to help generic drug applicants determine if they are eligible for 180-day marketing exclusivity for their products. This period of marketing exclusivity is generally provided to the first generic drug that challenges a patent for the innovator product.

 
Events
Pricing & Reimbursement Models

risksharing_150x150_master.gif

2nd Annual Pharmaceutical

Risk-Sharing & Value-Based Pricing & Reimbursement Models

April 15-16, 2010 - Vienna, Austria

There is clearly an increasing need for more innovative pricing and reimbursement agreements to help to balance the often conflicting objectives of pharmaceutical and medical technology manufacturers, payers, health technology assessors (HTA), physicians and patients. The industry faces a sustained increase in the cost of healthcare and an ever-increasing range of expensive drugs and technologies available as potential therapies.

Market Report
Emerging Biosimilars Landscape

business-insights-logo_275x48.gif

Biosimilars: Key developments in the regulatory environment

This report examines the structure of the biopharmaceutical industry and the strategic approaches taken to alleviate the threat posed by the biosimilar market. It also provides a comprehensive review of the current legislative and regulatory positions of key geographic regions in addition to evaluating their anticipated future legislative changes and outcomes.

Claim "10% Discount for Farmavita.Net Members" when purchasing this report!

 

 
Life Science Article
Clinical Trial in India

golden_temple_amritsar_punjab_india_by_balavenise.jpg

CLINICAL TRIAL IN INDIA-AN OVERVIEW


Global Pharmaceutical companies based in developed countries are increasingly turning to developing countries and emerging economies around the world for conducting clinical trials. Reduced costs combined with easy availability of patients with varied diseases makes developing countries favourite destinations for clinical research outsourcing.

The whole 9 pages article is available for download at Downloads section of FarmavitaR.com

Product Report
Biosimilars: Key developments in the regulatory environment

business-insights-logo_275x48.gif

Negotiating the Emerging Biosimilars Landscape: Key developments in the regulatory environment

As regulatory obstacles to biosimilars development have become increasingly resolved, a growing number of opportunities have been created for generics companies in the biopharmaceutical market, which according to IMS data was valued at $85.9 billion in 2007. Conservative projections estimate that sales of biopharmaceutical products will exceed $135 billion by 2011.

 
Advertisement
 

3D Content Cloud

BabelFish Translator




Click Flag for Translation

Sponsors

Member Log-in

Log-in to FarmavitaR+ community & network Membership is FREE!

Who's Online

Track Site Updates

Update me when site is updated

Subscribe to RSS


Regulatory Affairs

RA Section

Reports

Click to Reports

Events

Click to Events

Groups

Groups